Annovis Bio (ANVS) Competitors

Annovis Bio (NYSE:ANVS) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, community ranking, risk, earnings and media sentiment.

Do analysts recommend ANVS or AMLX?

Annovis Bio presently has a consensus target price of $32.17, suggesting a potential upside of 395.63%. Amylyx Pharmaceuticals has a consensus target price of $11.43, suggesting a potential upside of 119.36%. Given Annovis Bio's stronger consensus rating and higher probable upside, research analysts clearly believe Annovis Bio is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annovis Bio	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00
Amylyx Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.60

Which has more volatility and risk, ANVS or AMLX?

Annovis Bio has a beta of 1.7, meaning that its share price is 70% more volatile than the S&P 500. Comparatively, Amylyx Pharmaceuticals has a beta of -0.7, meaning that its share price is 170% less volatile than the S&P 500.

Does the media prefer ANVS or AMLX?

In the previous week, Amylyx Pharmaceuticals had 6 more articles in the media than Annovis Bio. MarketBeat recorded 10 mentions for Amylyx Pharmaceuticals and 4 mentions for Annovis Bio. Amylyx Pharmaceuticals' average media sentiment score of 0.90 beat Annovis Bio's score of -0.08 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annovis Bio	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amylyx Pharmaceuticals	2 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has preferable valuation and earnings, ANVS or AMLX?

Amylyx Pharmaceuticals has higher revenue and earnings than Annovis Bio. Annovis Bio is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annovis Bio	N/A	N/A	-$56.20M	-$4.46	-1.46
Amylyx Pharmaceuticals	$380.79M	0.94	$49.27M	-$3.82	-1.36

Do insiders and institutionals have more ownership in ANVS or AMLX?

15.8% of Annovis Bio shares are owned by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 32.3% of Annovis Bio shares are owned by insiders. Comparatively, 11.7% of Amylyx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Is ANVS or AMLX more profitable?

Annovis Bio has a net margin of 0.00% compared to Amylyx Pharmaceuticals' net margin of -17.86%. Amylyx Pharmaceuticals' return on equity of -36.97% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annovis Bio	N/A	-876.22%	-311.00%
Amylyx Pharmaceuticals	-17.86%	-36.97%	-29.61%

Does the MarketBeat Community favor ANVS or AMLX?

Amylyx Pharmaceuticals received 2 more outperform votes than Annovis Bio when rated by MarketBeat users. However, 96.77% of users gave Annovis Bio an outperform vote while only 65.31% of users gave Amylyx Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Annovis Bio	Outperform Votes 30 96.77%	Underperform Votes 1 3.23%
Amylyx Pharmaceuticals	Outperform Votes 32 65.31%	Underperform Votes 17 34.69%

Summary

Amylyx Pharmaceuticals beats Annovis Bio on 10 of the 17 factors compared between the two stocks.